HC Wainwright Issues Positive Estimate for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.29). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.14) EPS.

ALLO has been the subject of a number of other reports. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research note on Friday, March 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Allogene Therapeutics has an average rating of “Moderate Buy” and an average price target of $9.29.

Allogene Therapeutics Stock Down 0.6 %

Allogene Therapeutics stock opened at $1.62 on Friday. The business has a 50-day simple moving average of $1.89 and a two-hundred day simple moving average of $2.28. The company has a market cap of $351.97 million, a P/E ratio of -1.04 and a beta of 1.02. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.63.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.

Hedge Funds Weigh In On Allogene Therapeutics

Hedge funds have recently bought and sold shares of the business. Cibc World Markets Corp bought a new position in shares of Allogene Therapeutics during the 4th quarter worth $26,000. PAX Financial Group LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter worth $27,000. RPO LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter worth $31,000. Caption Management LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter worth $32,000. Finally, Syon Capital LLC purchased a new stake in Allogene Therapeutics in the fourth quarter valued at about $39,000. Institutional investors own 83.63% of the company’s stock.

Insider Buying and Selling

In other news, EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO David D. Chang sold 46,668 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the transaction, the chief executive officer now directly owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This represents a 0.88 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 104,866 shares of company stock valued at $194,461. Corporate insiders own 24.30% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).